基于的化疗疗效率在PARP抑制剂维持后对敏感性复发进行重新挑战

相关实验视频

Updated: Jun 13, 2025

04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K

Takehiro Nakao¹, Kenichi Harano^1,2, Masashi Wakabayashi³

¹Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Gynecologic oncology reports

|September 10, 2024

概括

基于的化疗再试剂对卵巢癌患者有效,其无间隔 (PFI) 超过6个月,即使在PARP抑制剂治疗后也是如此. 较长的PARP抑制剂治疗持续时间与随后的化疗更好的反应相关.

科学领域:

在瘤学瘤学.
妇科瘤学妇科瘤学
癌症治疗方法癌症治疗方法

背景情况:

无区间 (PFI) 对于确定卵巢癌复发的治疗策略至关重要.
对于PFI>6个月的患者,重新使用基于的化疗是标准的.
在用聚氨酸5'-二酸二糖聚合酶 (PARP) 抑制剂进行维持治疗后,这种策略的有效性尚不清楚.

研究的目的:

为了评估基于的化疗疗法的有效性,在接受了PARP抑制剂维持治疗的卵巢癌患者中重新挑战.
要确定在这种情况下,PFI标准的6个月的截止期是否仍然适用.

主要方法:

对10名患有PFI≥6个月的卵巢癌患者进行了回顾性分析,这些患者接受了PARP抑制剂维持疗法,随后进行了基于的化疗.
收集的数据包括PARP抑制剂的持续时间,对化疗再试剂的最佳反应 (通过RECIST 1.1评估) 和临床特征.
使用斯皮尔曼相关性来分析PARP抑制剂持续时间和治疗反应之间的关系.

主要成果:

七名患者接受了PARP抑制剂初级化疗后的化疗;三名患者因敏感性复发而接受.
中位数PFI为303.5天,中位数PARP抑制剂治疗持续时间为249天.
化学疗法重试导致完全响应 (10%),部分响应 (60%) 和稳定的疾病 (30%). 较长时间的PARP抑制剂治疗与更好的剂反应相关 (p=0.0288).

结论:

基于的化疗再试剂是对敏感卵巢癌患者的可行选择,保持6个月PFI值.
这种方法即使在PARP抑制剂维持疗法后达到PFI时也有效.
之前的PARP抑制剂治疗的持续时间可能会影响随后的基化疗的成功.

关键词:

维护维护维护维护卵巢癌是发生在卵巢中的癌症.这是一种PARP抑制剂.没有的时间间隔.重新挑战一个挑战

相关概念视频

02:56

Treatment Resistant Cancers

3.3K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.3K

02:37

Restarting Stalled Replication Forks

5.8K

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...

5.8K

02:57

Targeted Cancer Therapies

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...